Teva Pharmaceuticals has appointed Dr Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive VP to the newly created community and institutional affairs.
Dr De Notaristefani, who was most recently at Bristol-Myers Squibb (BMS), will have responsibility for Teva’s product supply and manufacturing network.
He will work closely with Frances Zipp, executive VP of quality, to ensure the company meets global standards, and will report directly to CEO Dr Jeremy Levin.
During his eight years at BMS, Dr De Notaristefani served as senior VP, API and international finishing operations for eight months before being promoted to president, technical operations and global support functions.
In this role, he was responsible for all manufacturing, technology and capital investments, supply chain, quality and compliance, procurement and information systems strategy and operations.
Prior to joining BMS, Dr De Notaristefani held several senior positions at Aventis in France and the US.
Referencing Teva’s previous record in compliance, Dr De Notaristefani said: “We will continue this practice as we begin to set the industry standard for regulatory compliance, customer service and cost effectiveness.”
Teva launches community and institutional affairs division
In addition to Dr De Notaristefani’s appointment, Teva also announced it has formed a division of community and institutional affairs to be headed by long-term Teva employee Arik Yaari.
He will lead the company’s efforts in social responsibility, philanthropy, institutional affairs and academic relations, and will develop a strategy to enhance Teva’s public image.
“This initiative is a priority for the company,” said Yaari. “I look forward to utilising my global experience and deep personal interest in these efforts to lead our network of collaborations with organizations such as foundations, and academic institutions, as well as with government and international agencies.”
Having joined Teva in 1981, Yaari has worked his way up through the company’s ranks, and was most recently group VP, Teva Generics Systems.
“Teva has a bright future, and I am confident Carlo and Arik will provide critical insight and expertise as the global healthcare market continues to evolve,” said CEO Dr Levin.